NCT06448962

Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 in Patients With Primary Hypercholesterolemia and Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 109 (actual)
• Sponsor: Addpharma Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Detailed description

Condition or disease : Primary Hypercholesterolemia and Essential Hypertension Intervention/treatment Drug : AD-2021 Drug : AD-2022 Drug : AD-2021 Placebo Drug : AD-2022 Placebo Phase : Phase 3

Conditions

• Hypertension, Essential
• Primary Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	AD-2021	PO, Once daily(QD), 8weeks
DRUG	AD-2022	PO, Once daily(QD), 8weeks
DRUG	AD-2021 Placebo	PO, Once daily(QD), 8weeks
DRUG	AD-2022 Placebo	PO, Once daily(QD), 8weeks

Timeline

• Start date: 2020-10-22
• Primary completion: 2021-11-22
• Completion: 2021-11-22
• First posted: 2024-06-07
• Last updated: 2024-06-07

Locations

1 site across 1 country: South Korea